KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Short term Debt: 2013-2025

Historic Short term Debt for Halozyme Therapeutics (HALO) over the last 9 years, with Sep 2025 value amounting to $710.7 million.

  • Halozyme Therapeutics' Short term Debt was N/A to $710.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $710.7 million, marking a year-over-year change of. This contributed to the annual value of $13.3 million for FY2022, which is 85.09% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Short term Debt stood at $710.7 million for Q3 2025, which was up 5,229.87% from $13.3 million recorded in Q4 2022.
  • Over the past 5 years, Halozyme Therapeutics' Short term Debt peaked at $710.7 million during Q3 2025, and registered a low of $13.3 million during Q3 2022.
  • Its 1-year average for Short term Debt is $710.7 million, with a median of $710.7 million in 2025.
  • As far as peak fluctuations go, Halozyme Therapeutics' Short term Debt surged by 3,014.45% in 2021, and later plummeted by 85.09% in 2022.
  • Halozyme Therapeutics' Short term Debt (Quarterly) stood at $89.4 million in 2021, then slumped by 85.09% to $13.3 million in 2022, then reached $710.7 million in 2025.
  • Its Short term Debt was $710.7 million in Q3 2025, compared to $13.3 million in Q4 2022 and $13.3 million in Q3 2022.